Ulixertinib, a Clinically Proven Safe & Effective ERK1/2 Inhibitor with Combination Therapy Potential for Overcoming Resistance via Reactivation of the MAPK Pathway
Time: 4:15 pm
day: Day One
Details:
• Safe and effective targeting of ERK1/2 in humans is possible with ulixertinib
• ERK inhibition provides the backbone for vertical combination treatment to overcome numerous MAPK reactivating resistance mechanisms
• ERK inhibition remains a critical option to be explored for patient benefit, both as first-line and to overcome RAS inhibitor resistance
